UNSPSC 51183301: Linagliptin

This classification denotes an anti-diabetic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3X29ZEJ4R2. European Medicines Agency schedules Linagliptin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB31340. Linagliptin generally arises in the molecular formula C25H28N8O2.

The term LINAGLIPTIN is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 23, no. 1, 2009, list 61.) As of Q4 2014, LINAGLIPTIN remains US FDA's Preferred Term for this commodity. Linagliptin bears US NLM identifiers UMLS ID C2746078 and NCI Concept Code C83887. SMILES: CC#CCN1C2=C(N=C1N3CCCC(C3)N)N(C(=O)N(C2=O)CC4=NC5=CC=CC=C5C(=N4)C)C.

UNSPSC 51183301 Linagliptin, a Commodity code, covers the supply of this specific diabetes medication and related generic pharmaceuticals through state and local government cooperative purchasing agreements. State and local governments procure linagliptin and similar therapeutic agents primarily through multistate cooperative contracts that bundle generic multi-source pharmaceuticals and OTC products for distribution across participating facilities. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents the primary issuing body identified in recent activity. These procurements target manufacturers and authorized distributors willing to supply products through established pharmaceutical wholesalers under fixed-price or net-price arrangements, with heavy weighting toward price competitiveness and compliance with cGMP and Drug Supply Chain Security Act standards.

The most recent opportunity under this code is MMCAP's Request for Proposal S1070000015802, posted January 20, 2026, with proposals due March 26, 2026. The solicitation establishes multiple contracts for generic multi-source pharmaceuticals including linagliptin, to be distributed across Minnesota, Oregon, and other participating MMCAP member jurisdictions beginning July 1, 2026. Vendors must maintain contractual relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, Morris & Dickson Co., LLC), demonstrate EDI capability, and commit to a 3 percent administrative fee. Evaluation emphasizes price competitiveness (75 percent weight), with the remaining 25 percent allocated to fixed pricing certainty, administrative compliance, EDI functionality, and fee agreement. All products must be FDA-compliant, hold expiration dates of at least one year from manufacture, and achieve market availability by May 15, 2026. The contract term runs two years for new vendors with optional MMCAP extensions, while incumbent responders' amendments extend through June 30, 2028.